SCHEMBL3087475

SCHEMBL3087475

NC(=O)c1ccccc1[CH]CC1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
MAPT P10636 2/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PARP15 Q460N3 1/20 0.38
PARP10 Q53GL7 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
LMNA P02545 2/20 0.38
METAP2 P50579 1/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BCAT2 O15382 1/20 0.37
PARP1 P09874 5/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7527880 0.77 ALDH1A1 (0.47) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL176644 0.77 BCAT2 (0.47) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL4704450 0.77 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL14696612 0.76 ACHE (0.41) L3MBTL1NPC1
SCHEMBL3282649 0.75 KDM4E (0.45) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL176816 0.75 KDM4E (0.45) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL9903444 0.75 KDM4E (0.45) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL3324835 0.75 KDM4E (0.41) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL14696160 0.74 TP53 (0.44) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL14813627 0.74 KDM4E (0.45) KDM4EALDH1A1HPGDMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US claimed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 KDM4E 2560/4885ALDH1A1 480/4885HPGD 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.